DESCRIPTION:
FiteBac® K18/MMA
10% K18 formulated in liquid MMA
USE:
Liquid MMA component for
2-part acrylate system
TARGET AUDIENCE:
Dental Laboratories
DEVELOPMENT STATUS:
Cleared for use in dental acrylics
PLANNED COMMERCIAL INTRODUCTION:
Q1/2019
BENEFITS:
Manufacture of dentures and retainers with long term antimicrobial resistance to biofilm formation.
DESCRIPTION:
FiteBac® Cavity Cleanser
2% K21 in a solvent base formulation
USE:
Preparation of tooth prior to placement of dental restoration
TARGET AUDIENCE:
Dental Offices
DEVELOPMENT STATUS:
510(k) Submission
Q1/2018
PLANNED COMMERCIAL INTRODUCTION:
Q1/2019
BENEFITS:
Reduced sensitivity and microbiological presence at prepared dentin layer. Stable hybrid layer at dentin-restoration interface.
DESCRIPTION:
FiteBac® OrthoBond
5% K18 in a temporary orthodontic dental adhesive
USE:
Temporarily placement of orthodontic appliances
TARGET AUDIENCE:
Dental Offices
DEVELOPMENT STATUS:
510(k) Submission
Q2/2018
PLANNED COMMERCIAL INTRODUCTION:
Q1/2019
BENEFITS:
Resistance to biofilm formation around and under orthodontic brackets. Reduce risk of surface damage to surface enamel of teeth. Improved cosmetic outcomes.
DESCRIPTION:
FiteBac® Bond
5% K18 in a permanent acrylic based dental adhesive
USE:
Permanent placement of dental appliances and restorations
TARGET AUDIENCE:
Dental Offices
DEVELOPMENT STATUS:
510(k) submission
Q2/2018
PLANNED COMMERCIAL INTRODUCTION:
Q1/2019
BENEFITS:
Resistance to biofilm formation, loss of adhesion and decay under permanent dental restorations.